Glibenclamide tablets

DRUG2 trials

Sponsors

Xijing Hospital, CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Conditions

Healthy SubjectsIntracerebral Hemorrhage

Phase 1

A Study to Evaluate the DDI of DBPR108 With Metformin,Glibenclamide,Valsartan, or Simvastatin in Healthy Subjects

CompletedNCT04859452

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Healthy Subjects

Start: 2021-05-26End: 2021-07-09Updated: 2021-07-20

Unknown Phase

Glibenclamide Advantage in Treating Edema After Intracerebral Hemorrhage

CompletedNCT03741530

Xijing HospitalIntracerebral Hemorrhage

Start: 2018-12-15End: 2020-09-23Updated: 2022-04-08

Related Papers

Efficacy and safety of glibenclamide therapy after intracerebral haemorrhage (GATE-ICH): A multicentre, prospective, randomised, controlled, open-label, blinded-endpoint, phase 2 clinical trial.

2022-09-2318 citations

Glibenclamide Advantage in Treating Edema After Intracerebral Hemorrhage (GATE-ICH): Study Protocol for a Multicenter Randomized, Controlled, Assessor-Blinded Trial

Frontiers in Neurology2021-04-279 citations